Put your knowledge to the test and see how you stack up relative to your fellow clinicians! Challenge yourself with this self-paced interactive assessment designed to sharpen your knowledge and competency in the diagnosis and management of idiopathic pulmonary fibrosis. The Formative Assessment platform profiles individual learning needs related to the management of IPF and recommends personalized education to meet each learner’s unique needs.
This activity consists of three modules, each taking approximately 15 minutes to complete:
1. Diagnosis and Disease Course
2. Therapy
3. Care Plans
Take a moment to listen to the audio clips below to meet our patient advocate and IPF caregiver; you will hear their stories featured throughout each module:
After completing the IPF Formative Assessment, empower your patients with the complementary patient/caregiver educational resource: Living Well with IPF: Strategies to Become Your Best Patient Advocate. This activity is designed to equip patients and their caregivers with the resources and education needed for optimal IPF management and improved quality of life. Click here for more information.
Given the increasing prevalence of IPF in the United States, clinician education is needed on IPF diagnosis and management. This fatal disease has a median survival rate of 2-5 years and is characterized by a chronic, progressive fibrosing interstitial pneumonia of unknown cause. The IPF Formative Assessment affords clinicians the knowledge and skills needed to enact timely, accurate IPF diagnoses and develop comprehensive management strategies that will improve IPF patient quality of life.
This activity is intended for pulmonologists and other clinicians interested in the treatment of patients with IPF.
Upon completion of each module, participants will be able to:
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Diagnosis and Disease Course:
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Therapy:
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Care Plans:
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit is awarded upon completion of each module. To receive credit, participants are required to answer a short series of questions, review their performance and the correct answer rationales, and complete an evaluation. A certificate will be immediately available. There is no fee to participate in the IPF Formative Assessment or for the generation of the certificates.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
The following financial relationships have been provided:Imre Noth, MD
Advisor: Boehringer Ingelheim, Genentech
Consultant: Boehringer Ingelheim, Genentech, and Sanofi
Speakers' Bureau: Boehringer Ingelheim and Genentech
Cathy Brown, RN
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
For questions, please contact Katlyn Cooper at kcooper@achlcme.org
